Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery

All NewsApril 16, 2025

Merck signs deal with Austria’s Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent